Literature DB >> 3484479

Studies of structure-activity relationships of human interleukin-2.

S M Liang, D R Thatcher, C M Liang, B Allet.   

Abstract

Human interleukin-2 (IL-2) has 3 cysteine residues; cysteines 58 and 105 form an intramolecular disulfide bridge, whereas cysteine 125 has a free sulfhydryl group. In this study, site-specific mutagenesis has been used to modify the cysteine residues of recombinant Escherichia coli-derived IL-2 (rIL-2) to evaluate the functional structure of IL-2. Substitution or deletion of cysteine 105 disrupted the disulfide bridge and yielded a mutant protein which was 8-10 times less active than wild type rIL-2. A similar modification at position 58, however, reduced the activity of rIL-2 by more than 250-fold. Although substitution of serine for cysteine 125 did not affect IL-2 activity, deletion of cysteine 125 or deletion of amino acids in the vicinity of this cysteine yielded mutant proteins with little, if any, activity. These results indicate that the protein structure in the vicinity of both positions 58 and 125 is more critical than that close to position 105. These findings may provide a clue to the understanding of the functional structure of human IL-2.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484479

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Regulation by glutathione of interleukin-4 activity on cytotoxic T cells.

Authors:  S M Liang; N Lee; D S Finbloom; C M Liang
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

2.  Insufficient (sub-native) helix content in soluble/solid aggregates of recombinant and engineered forms of IL-2 throws light on how aggregated IL-2 is biologically active.

Authors:  Uzma Fatima; Balvinder Singh; Karthikeyan Subramanian; Purnananda Guptasarma
Journal:  Protein J       Date:  2012-10       Impact factor: 2.371

3.  Protein engineering and site-directed mutagenesis. Patents and literature.

Authors:  R J Linhardt
Journal:  Appl Biochem Biotechnol       Date:  1986-08       Impact factor: 2.926

4.  Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors.

Authors:  R J Robb; C M Rusk; J Yodoi; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor.

Authors:  L Collins; W H Tsien; C Seals; J Hakimi; D Weber; P Bailon; J Hoskings; W C Greene; V Toome; G Ju
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

6.  Engineered interleukin-2 antagonists for the inhibition of regulatory T cells.

Authors:  David V Liu; Lisa M Maier; David A Hafler; K Dane Wittrup
Journal:  J Immunother       Date:  2009 Nov-Dec       Impact factor: 4.456

7.  Purification and renaturation of recombinant human interleukin-2.

Authors:  M P Weir; J Sparks
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

8.  Receptor binding properties of four-helix-bundle growth factors deduced from electrostatic analysis.

Authors:  E Demchuk; T Mueller; H Oschkinat; W Sebald; R C Wade
Journal:  Protein Sci       Date:  1994-06       Impact factor: 6.725

9.  Identification of three critical regions within mouse interleukin 2 by fine structural deletion analysis.

Authors:  S M Zurawski; G Zurawski
Journal:  EMBO J       Date:  1988-04       Impact factor: 11.598

10.  Characterization of a novel human tumor necrosis factor-alpha mutant with increased cytotoxic activity.

Authors:  T Masegi; A Kato; K Kitai; M Fukuoka; H Ogawa; Y Ichikawa; S Nakamura; N Watanabe; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1995-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.